ZENITH DRUGS LIMIT Stock Price Today (NSE: ZENITHDRUG)
Fundamental Score
ZENITH DRUGS LIMIT Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ZENITH DRUGS LIMIT share price today is ₹38.45, up +0.00% on NSE/BSE as of 14 April 2026. ZENITH DRUGS LIMIT (ZENITHDRUG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹89.17 (Cr). The 52-week high for ZENITHDRUG share price is ₹92.75 and the 52-week low is ₹33.30. At a P/E ratio of 20.98x, ZENITHDRUG is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.11% and a debt-to-equity ratio of 0.72.
ZENITH DRUGS LIMIT Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma play dependent on government contracts; high risk, potentially high reward.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Zenith Drugs secured a tender from the Karnataka government for ₹2.90 Cr worth of levocetirizine syrup bottles. Prior to that, on April 2nd, they announced securing an order valued at ₹29 million. On April 8th, there was an announcement regarding disclosure under SEBI Takeover Regulations. 🧠 CORE STORY (THE REAL GAME): Zenith Drugs is riding the wave of increased government healthcare spending and contract manufacturing, aiming to become a key supplier of pharmaceutical formulations. The market is pricing in consistent order wins and revenue growth from government contracts. 🔥 WHAT IS DRIVING THE STOCK: 1. **Government Tenders:** Recent wins in Karnataka (₹2.90 Cr) and the earlier order worth ₹29 million demonstrate Zenith's ability to secure government contracts. 2. **Capacity Expansion:** The new oncology facility, expected to contribute from FY27, is anticipated to boost margins. 3. **Revenue Growth:** The company has shown decent revenue growth in the past, with FY24 revenue reaching ₹133.74 Cr. ⚖️ BULL vs BEAR: Bull: Consistent government orders and the upcoming oncology facility will drive revenue and margin expansion. Increased capacity utilization will lead to higher profitability. Bear: Micro-cap with high promoter holding limits float. Negative free cash flow of ₹-64.04 Cr over the last 5 years. Dependence on government tenders creates revenue concentration risk. Any quality control issues or delays in the oncology facility could tank the stock. Latest quarter YoY profit was down -55.24%. 💣 WHAT MARKET IS PRICING: The market is pricing in continued government order wins and a successful ramp-up of the new oncology facility. If order flow slows or the facility faces delays, expect a sharp correction. 🎯 BOTTOM LINE: Zenith Drugs is a micro-cap play on government healthcare spending, but liquidity risk and reliance on tenders make it a high-risk, high-reward bet.
- Recent government order wins (Karnataka, ₹2.90 Cr)
- Upcoming oncology facility to boost margins
- Positive revenue growth in FY24 (₹133.74 Cr)
- New, larger government contracts
- Successful commissioning of the oncology facility
- Improved capacity utilization and profitability
- Micro/SME cap = liquidity risk
- Negative free cash flow (₹-64.04 Cr)
- High promoter holding limits float
FII down -0.06%. No major institutional interest.
Indian pharma sector projected to reach $130 billion by 2030, but US market conditions may dent earnings.
Zenith won a Karnataka government tender for ₹2.90 Cr worth of levocetirizine syrup bottles.
No. Free Cash Flow 5Y: ₹-64.04 Cr.
Next 3-6 months hinge on securing more government orders and progress on the oncology facility. Watch for revenue growth and margin improvement.
Primary Thesis Risk
Reliance on government tenders creates significant revenue concentration risk.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
ZENITH DRUGS LIMIT Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
ZENITH DRUGS LIMIT Share Price Analysis: A ROCE Efficiency Perspective
The pharmaceutical sector is currently experiencing a significant shift towards personalized medicine, driving demand for specialized drug formulations and impacting Return on Capital Employed (ROCE) dynamics across the industry. This analysis focuses on ZENITH DRUGS LIMIT share price (₹49.0) and its financial performance through the lens of ROCE efficiency. A key metric for investors, ROCE illustrates how effectively a company generates profits from its capital. With a current Price-to-Earnings (PE) ratio of 20.98 and a ROCE of 12.9%, ZENITH DRUGS LIMIT presents a specific financial profile within the competitive landscape.
A crucial aspect of sustainable value creation lies in maintaining a robust ROCE. ZENITH DRUGS LIMIT's ROCE of 12.9% indicates its current efficiency in deploying capital. This metric is important in evaluating the company's competitive moat. A higher ROCE typically suggests a stronger ability to reinvest profits at attractive rates of return, creating a virtuous cycle of growth. However, it is essential to benchmark this against peers like
Mankind Pharma Ltd and consider the broader industry average to assess its true significance.When comparing ZENITH DRUGS LIMIT to its competitors, it's beneficial to also analyze factors such as perceived management quality. Companies like Mankind Pharma Ltd often command a premium valuation due to market perception of superior leadership and strategic execution, which can directly influence investor confidence and ultimately, ROCE sustainability. These considerations are vital for investors when evaluating the long-term prospects of ZENITH DRUGS LIMIT.
The 12.9% ROCE of ZENITH DRUGS LIMIT impacts its moat by determining its capacity to fund research and development, acquire new assets, or return capital to shareholders. A consistent and growing ROCE strengthens its competitive positioning. A declining or stagnant ROCE, on the other hand, may signal eroding profitability or inefficiencies in capital allocation. It's essential to continually monitor these trends and compare them to competitors such as Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd to gain a complete picture of ZENITH DRUGS LIMIT's relative performance. This analysis forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ZENITH DRUGS LIMIT Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZENITHDRUG across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Attractive Valuation (P/E: 20.98 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (15.56%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Profit Growth Track Record (16.61% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (69.98%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-55.24%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (2.27x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-64.04 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
ZENITH DRUGS LIMIT Financial Statements
Comprehensive financial data for ZENITH DRUGS LIMIT including income statement, balance sheet and cash flow
About ZENITHDRUG (ZENITH DRUGS LIMIT)
ZENITH DRUGS LIMIT (ZENITHDRUG) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a c...urrent market capitalisation of ₹89.17 (Cr). ZENITH DRUGS LIMIT has delivered a Return on Equity (ROE) of 11.11% and a ROCE of 12.90%. The debt-to-equity ratio stands at 0.72, reflecting the company's capital structure. Investors tracking ZENITHDRUG share price can monitor key metrics including P/E ratio, promoter holding of 69.98%, and quarterly earnings growth.
Company Details
ZENITHDRUG Share Price: Frequently Asked Questions
What is the current share price of ZENITH DRUGS LIMIT (ZENITHDRUG)?
As of 14 Apr 2026, 11:00 am IST, ZENITH DRUGS LIMIT share price is ₹38.45. The ZENITHDRUG stock has a market capitalisation of ₹89.17 (Cr) on NSE/BSE.
Is ZENITHDRUG share price Overvalued or Undervalued?
ZENITHDRUG share price is currently trading at a P/E ratio of 20.98x, compared to the industry average of 31.77x. Based on this relative valuation, the ZENITH DRUGS LIMIT stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ZENITHDRUG share price?
The 52-week high of ZENITHDRUG share price is ₹92.75 and the 52-week low is ₹33.30. These values are updated daily from NSE/BSE price data.
What factors affect the ZENITH DRUGS LIMIT share price?
Key factors influencing ZENITHDRUG share price include quarterly earnings growth (Sales Growth: 15.56%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is ZENITH DRUGS LIMIT a good stock for long-term investment?
ZENITH DRUGS LIMIT shows a 5-year Profit Growth of 16.61% and an ROE of 11.11%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.72 before investing in ZENITHDRUG shares.
How does ZENITH DRUGS LIMIT compare with its industry peers?
ZENITH DRUGS LIMIT competes with major peers in the Pharmaceuticals. Investors should compare ZENITHDRUG share price P/E of 20.98x and ROE of 11.11% against the industry averages to determine competitive standing.
What is the P/E ratio of ZENITHDRUG and what does it mean?
ZENITHDRUG share price has a P/E ratio of 20.98x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is ZENITHDRUG performing according to Bull Run's analysis?
ZENITHDRUG has a Bull Run fundamental score of 39/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ZENITHDRUG belong to?
ZENITHDRUG operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting ZENITH DRUGS LIMIT share price.
What is Return on Equity (ROE) and why is it important for ZENITHDRUG?
ZENITHDRUG has an ROE of 11.11%, which shows decent profitability but room for improvement. ROE measures how efficiently ZENITH DRUGS LIMIT generates profits from shareholders capital.
How is ZENITHDRUG debt-to-equity ratio and what does it indicate?
ZENITHDRUG has a debt-to-equity ratio of 0.72, which indicates moderate leverage that should be monitored.
What is ZENITHDRUG dividend yield and is it a good dividend stock?
ZENITHDRUG offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in ZENITH DRUGS LIMIT shares.
How has ZENITHDRUG share price grown over the past 5 years?
ZENITHDRUG has achieved 5-year growth rates of: Sales Growth 11.10%, Profit Growth 16.61%, and EPS Growth N/A%.
What is the promoter holding in ZENITHDRUG and why does it matter?
Promoters hold 69.98% of ZENITHDRUG shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in ZENITH DRUGS LIMIT.
What is ZENITHDRUG market capitalisation category?
ZENITHDRUG has a market capitalisation of ₹89 crores, placing it in the Small-cap category.
How volatile is ZENITHDRUG stock?
ZENITHDRUG has a beta of N/A. A beta > 1 suggests the ZENITH DRUGS LIMIT stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ZENITHDRUG operating profit margin trend?
ZENITHDRUG has a 5-year average Operating Profit Margin (OPM) of 9.94%, indicating the company's operational efficiency.
How is ZENITHDRUG quarterly performance?
Recent quarterly performance shows ZENITH DRUGS LIMIT YoY Sales Growth of 15.56% and YoY Profit Growth of -55.24%.
What is the institutional holding pattern in ZENITHDRUG?
ZENITHDRUG has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the ZENITH DRUGS LIMIT stock.